469 related articles for article (PubMed ID: 27671969)
21. Long-term treatment of transsexuals with cross-sex hormones: extensive personal experience.
Gooren LJ; Giltay EJ; Bunck MC
J Clin Endocrinol Metab; 2008 Jan; 93(1):19-25. PubMed ID: 17986639
[TBL] [Abstract][Full Text] [Related]
22. Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration.
Seiger R; Hahn A; Hummer A; Kranz GS; Ganger S; Woletz M; Kraus C; Sladky R; Kautzky A; Kasper S; Windischberger C; Lanzenberger R
Psychoneuroendocrinology; 2016 Dec; 74():371-379. PubMed ID: 27744092
[TBL] [Abstract][Full Text] [Related]
23. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM
Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141
[TBL] [Abstract][Full Text] [Related]
24. TESTOSTERONE LEVELS ACHIEVED BY MEDICALLY TREATED TRANSGENDER WOMEN IN A UNITED STATES ENDOCRINOLOGY CLINIC COHORT.
Liang JJ; Jolly D; Chan KJ; Safer JD
Endocr Pract; 2018 Feb; 24(2):135-142. PubMed ID: 29144822
[TBL] [Abstract][Full Text] [Related]
25. Antiandrogen or estradiol treatment or both during hormone therapy in transitioning transgender women.
Haupt C; Henke M; Kutschmar A; Hauser B; Baldinger S; Saenz SR; Schreiber G
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013138. PubMed ID: 33251587
[TBL] [Abstract][Full Text] [Related]
26. MANAGEMENT OF ENDOCRINE DISEASE: Optimal feminizing hormone treatment in transgender people.
Glintborg D; T'Sjoen G; Ravn P; Andersen MS
Eur J Endocrinol; 2021 Jun; 185(2):R49-R63. PubMed ID: 34081614
[TBL] [Abstract][Full Text] [Related]
27. Self-perception of voice in transgender persons during cross-sex hormone therapy.
Bultynck C; Pas C; Defreyne J; Cosyns M; den Heijer M; T'Sjoen G
Laryngoscope; 2017 Dec; 127(12):2796-2804. PubMed ID: 28730692
[TBL] [Abstract][Full Text] [Related]
28. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.
Laliberté F; Dea K; Duh MS; Kahler KH; Rolli M; Lefebvre P
Menopause; 2011 Oct; 18(10):1052-9. PubMed ID: 21775912
[TBL] [Abstract][Full Text] [Related]
29. Cross-sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare.
Bretherton I; Thrower E; Grossmann M; Zajac JD; Cheung AS
Intern Med J; 2019 Feb; 49(2):182-188. PubMed ID: 29992681
[TBL] [Abstract][Full Text] [Related]
30. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study.
Vita R; Settineri S; Liotta M; Benvenga S; Trimarchi F
Maturitas; 2018 Jan; 107():92-96. PubMed ID: 29169588
[TBL] [Abstract][Full Text] [Related]
31. Transgender patients and the role of the coagulation clinician.
Connors JM; Middeldorp S
J Thromb Haemost; 2019 Nov; 17(11):1790-1797. PubMed ID: 31465627
[TBL] [Abstract][Full Text] [Related]
32. Assessing and Addressing the Risk of Venous Thromboembolism Across the Spectrum of Gender Affirming Care: A Review.
Arrington-Sanders R; Connell NT; Coon D; Dowshen N; Goldman AL; Goldstein Z; Grimstad F; Javier NM; Kim E; Murphy M; Poteat T; Radix A; Schwartz A; St Amand C; Streed CG; Tangpricha V; Toribio M; Goldstein RH
Endocr Pract; 2023 Apr; 29(4):272-278. PubMed ID: 36539066
[TBL] [Abstract][Full Text] [Related]
33. Gonadal suppressive and cross-sex hormone therapy for gender dysphoria in adolescents and adults.
Smith KP; Madison CM; Milne NM
Pharmacotherapy; 2014 Dec; 34(12):1282-97. PubMed ID: 25220381
[TBL] [Abstract][Full Text] [Related]
34. Hormone therapy and risk of venous thromboembolism among postmenopausal women.
Canonico M
Maturitas; 2015 Nov; 82(3):304-7. PubMed ID: 26276103
[TBL] [Abstract][Full Text] [Related]
35. Specific oral contraceptive use and venous thromboembolism resulting in hospital admission.
Heuser P; Tonga K; Hopkins R; Henderson M; Weatherall M; Metcalfe S; Beasley R
N Z Med J; 2004 Nov; 117(1206):U1176. PubMed ID: 15570345
[TBL] [Abstract][Full Text] [Related]
36. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study.
Dinger J; Assmann A; Möhner S; Minh TD
J Fam Plann Reprod Health Care; 2010 Jul; 36(3):123-9. PubMed ID: 20659364
[TBL] [Abstract][Full Text] [Related]
37. Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy.
Martinez-Martin FJ; Kuzior A; Hernandez-Lazaro A; de Leon-Durango RJ; Rios-Gomez C; Santana-Ojeda B; Perez-Rivero JM; Fernandez-Trujillo-Comenge PM; Gonzalez-Diaz P; Arnas-Leon C; Acosta-Calero C; Perdomo-Herrera E; Tocino-Hernandez AL; Del Sol Sanchez-Bacaicoa M; Del Pino Perez-Garcia M
Hypertens Res; 2023 Jan; 46(1):219-225. PubMed ID: 36229533
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of antiandrogens and feminization in transgender women.
Angus LM; Nolan BJ; Zajac JD; Cheung AS
Clin Endocrinol (Oxf); 2021 May; 94(5):743-752. PubMed ID: 32926454
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
